-
公开(公告)号：EP3434678A1
公开(公告)日：2019-01-30
申请号：EP17769445.2
申请日：2017-03-22
发明人： LIU, Hong , WANG, Jiang , LI, Jian , LI, Jia , LI, Jingya , JIANG, Hualiang , LUO, Xiaomin , CHEN, Kaixian
IPC分类号： C07D495/04 , A61K31/519 , A61P3/10 , A61P9/12 , A61P9/10 , A61P13/12 , A61P25/00 , A61P9/00 , A61P27/02
摘要： The present invention relates to a salt form of (R)-methyl-2-(3-aminopiperidin-1 -yl)-3-(2-cyanobenzyl)-4-carbonyl-3,4-dihydrothioph ene[3,2-d]pyrimidine-6-carboxylic acid and a preparation method for the salt form. Also disclosed is a pharmaceutical composition of the formula I compound salt form. The salt form of the present invention provides powerful in vivo hypoglycemic activity and is expected to be a novel pharmaceutical active ingredient for treating or preventing diabetes mellitus type 2 and/or complications of diabetes mellitus type 2
-
22.发明授权ALPHA-AMINO-N-SUBSTITUTED AMIDES, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USES THEREOF 有权α-氨基的N-取代酰胺，药物组合物，其这包含，及其用途
公开(公告)号：EP2233467B1
公开(公告)日：2012-09-19
申请号：EP08858616.9
申请日：2008-12-11
发明人： NAN, Fajun , LI, Jia , DING, Jian , LIU, Gang , XIE, Chuanming , MIAO, Zehong , TAI, Wanyi
IPC分类号： C07C237/16 , C07C233/05 , C07C233/09 , C07C233/18 , C07C233/20 , A61K31/16 , A61P35/00
CPC分类号： C07C237/22 , C07C247/12 , C07C271/22 , C07C323/60 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2603/74 , C07D209/14 , C07D209/20 , C07D233/54 , C07D307/24 , C07D307/94
-
23.发明公开
公开(公告)号：EP3896062A1
公开(公告)日：2021-10-20
申请号：EP19893951.4
申请日：2019-12-06
发明人： CHEN, Xiaohua , LI, Jia , CHENG, Yu , ZHOU, Yubo , NIE, Huijun , WANG, Yujie , GUO, Andi , KAN, Weijuan
IPC分类号： C07D401/04 , C07D401/14 , A61K31/4412 , A61K31/4745 , A61P35/00
摘要： The present invention relates to an isoindoline compound as represented by general formula (I) and used as a CRBN regulator, and a preparation method, a pharmaceutical composition, and an application of the isoindoline compound. Specifically, a class of polysubstituted isoindoline compound provided in the present invention, as a class of CRL4 CRBN E3 ubiquitin ligase regulator having a novel structure, has good anti-tumor activity and immunoregulatory activity, and can be used for preparing drugs for treating diseases associated with a CRL4 CRBN E3 ubiquitin ligase.
-
公开(公告)号：EP3214079B1
公开(公告)日：2020-06-24
申请号：EP15855852.8
申请日：2015-10-30
申请人： East China University Of Science And Technology , Shanghai Institute of Materia Medica, Chinese Academy of Sciences
发明人： LI, Honglin , JIANG, Hualiang , XU, Yufang , LI, Jia , ZHAO, Zhenjiang , LI, Jingya , XU, Hongling , LI, Shiliang
IPC分类号： C07D311/92 , C07D405/04 , C07D417/04 , C07D221/10 , C07D335/04 , A61K31/352 , A61K31/5377 , A61P3/00 , A61P3/10 , A61P7/10 , A61P29/00
-
公开(公告)号：EP3421447A1
公开(公告)日：2019-01-02
申请号：EP17755775.8
申请日：2017-02-20
发明人： NAN, Fajun , LI, Jia , LI, Jingya , ZHANG, Mei , XIE, Zhifu , WANG, Jingtao , GUO, Dongdong
IPC分类号： C07C57/13 , C07C61/35 , C07C57/42 , C07C55/28 , C07C51/09 , A61K31/194 , A61P3/04 , A61P3/10
摘要： The present invention relates to a class of fatty acid compounds, a preparation method thereof and use thereof. The fatty acid compounds have the structure of the formula I, which has the ability to activate APMK and inhibit the glucose output in mouse primary hepatocytes. The fatty acid compounds can be used in preparing a medicament for the treatment of obesity or diabetes.
-
公开(公告)号：EP3405192A1
公开(公告)日：2018-11-28
申请号：EP17741819.1
申请日：2017-01-17
申请人： Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. , Shanghai Institute of Materia Medica, Chinese Academy of Sciences
发明人： LIAO, Xibin , LI, Jia , LU, Zhijian , ZHOU, Yubo , GAO, Anhui
IPC分类号： A61K31/415 , C07D471/04 , C07D231/00
CPC分类号： C07D471/04 , A61K31/437 , A61K45/06 , C07D231/56 , A61K2300/00
摘要： Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I).
-
公开(公告)号：EP3127903B1
公开(公告)日：2017-08-23
申请号：EP15774232.1
申请日：2015-03-27
发明人： NAN, Fajun , LI, Jia , XIE, Xin , GONG, Chaojun , ZHOU, Yubo , CHAI, Hui , ZHANG, Yangming , SU, Mingbo
IPC分类号： C07D277/56 , C07D277/60 , C07D417/04 , A61K31/428 , A61K31/427 , A61P37/02 , A61P35/00 , A61P35/02
CPC分类号： C07D277/56 , C07D277/60 , C07D277/66 , C07D417/04 , C07D417/14
-
28.发明公开ALPHA-AMINO-N-SUBSTITUTED AMIDES, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USES THEREOF 有权α-氨基的N-取代酰胺，药物组合物，其这包含，及其用途
公开(公告)号：EP2233467A1
公开(公告)日：2010-09-29
申请号：EP08858616.9
申请日：2008-12-11
发明人： NAN, Fajun , LI, Jia , DING, Jian , LIU, Gang , XIE, Chuanming , MIAO, Zehong , TAI, Wanyi
IPC分类号： C07C237/16 , C07C233/05 , C07C233/09 , C07C233/18 , C07C233/20 , A61K31/16 , A61P35/00
CPC分类号： C07C237/22 , C07C247/12 , C07C271/22 , C07C323/60 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2603/74 , C07D209/14 , C07D209/20 , C07D233/54 , C07D307/24 , C07D307/94
摘要： The present invention relates to filed of pharmaceutical chemistry. Disclosed are a series of α-amino-N-substituted amide compounds having a structure of the following formula, the pharmaceutically acceptable salts thereof, and the pharmaceutical composition comprising the same. The α-amino-N-substituted amide compounds or the pharmaceutically acceptable salts thereof according to the present invention have anti-tumor and/or anti-cancer activities in vivo and in vitro, can effectively depress the growth of various tumor cells and/or cancer cells, and thus can be used in preparing drugs for treating tumors and/or cancers.
-
29.发明公开PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR, PREPARATION METHODS AND USES THEREOF 审中-公开抑制剂VON蛋白磷酸化酶1B，HERSTELLUNGSVERFAHREN UND ANWENDUNGEN DAVON
公开(公告)号：EP2133342A1
公开(公告)日：2009-12-16
申请号：EP08706537.1
申请日：2008-02-26
发明人： NAN, Fajun , LI, Jia , WEI, Yi , ZHANG, Wei , LI, Jingya , SHI, Lei
IPC分类号： C07D277/22 , C07D263/32 , C07D213/55 , C07D417/12 , A61K31/426 , A61K31/427 , A61K31/421 , A61K31/44 , A61P3/04 , A61P3/10
CPC分类号： C07D277/30 , C07D417/12
摘要： PTP1B inhibitors with the following structure (formula I). Experiments indicate that these inhibitors can effectively inhibit the activity of protein tyrosine phosphatase 1B (PTP1B). They can be used as insulin sensitisers. They can be used to prevent, delay or treat diseases which are related to insulin antagonism mediated by PTP1B, especially diabetes type II and obesity. The invention also provides methods for preparing these inhibitors.
摘要翻译： 具有以下结构的PTP1B抑制剂（式I）。 实验表明，这些抑制剂可有效抑制蛋白酪氨酸磷酸酶1B（PTP1B）的活性。 它们可以用作胰岛素敏化剂。 它们可用于预防，延迟或治疗与PTP1B介导的胰岛素拮抗相关的疾病，特别是II型糖尿病和肥胖症。 本发明还提供了制备这些抑制剂的方法。
-
30.发明公开
公开(公告)号：EP4458820A1
公开(公告)日：2024-11-06
申请号：EP22914967.9
申请日：2022-12-28
发明人： LIU, Hong , LI, Jia , WANG, Jiang , ZANG, Yi , CHEN, Feiyang , GAO, Lixin , ZHAO, Jing , SUN, Dandan , WANG, Ke'an , JIANG, Hualiang , XIE, Rongrong
IPC分类号： C07D403/12 , C07D403/14 , C07D401/12 , C07D401/14 , C07D407/14 , C07C409/14 , C07D471/00 , C07D405/14 , C07K14/705 , C07K14/72 , A61K31/53 , A61P1/16 , A61P9/10 , A61P9/12 , A61P3/04 , A61P3/06 , A61P3/10 , A61P3/00 , A61P9/00
摘要： Provided in the present invention are a class of quinoline compounds and a preparation method therefor, a pharmaceutical composition and the use thereof. Specifically, provided in the present invention are a compound as shown in formula(I), and a stereoisomer, a deuterated compound, a solvate, a metabolite, a pharmaceutically acceptable salt, a eutectic or a prodrug thereof, and a pharmaceutical composition thereof. Further provided in the present invention are a preparation method for the compound and the use thereof in the preparation of a drug for treating diseases mediated by thyroid hormone receptors. Related diseases include, but are not limited to, diseases such as non-alcoholic fatty liver diseases, atherosclerosis, coronary heart disease, hypertension, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, obesity, diabetes, metabolic disorders, lipid metabolism disorders, 1A type glycogen storage diseases, hypothyroidism and thyroid cancer.
-
-
-
-
-
-
-
-
-
搜索结果
38 条记录 (耗时 0.027 秒)
